T9G (T9G)

Overview

Vidac Pharma Holding Plc operates as an investment holding company primarily focused on the discovery and development of pharmaceutical treatments targeting oncologic (cancer-related) and dermatologic diseases. Founded in 2021 with its headquarters situated in London, United Kingdom, the company leverages its expertise to develop innovative therapies that address significant unmet medical needs in the oncology and dermatology sectors. Through its dedication to research and development, Vidac Pharma aims to bring forth new options for patients battling life-threatening diseases by targeting the disease at its source with minimal impact on healthy cells.

Products and Services

• VDA-1102 Ointment

  This anti-neoplastic agent is currently under Phase 2 clinical trials. VDA-1102 ointment is designed to induce apoptosis (programmed cell death) specifically in cancer cells, while limiting the effects on surrounding healthy cells. Its unique mechanism makes it potentially beneficial for treating a wide variety of cancers with fewer side effects compared to traditional treatments.

• VDA-1102 IV

  An intravenous formulation of the VDA-1102, this anti-neoplastic agent shares the same goal of triggering apoptosis in cancer cells but is suitable for conditions or tumor types that may not be effectively treated with a topical application. This variation of VDA-1102 is still in the development phase, focusing on broadening the application of Vidac Pharma's apoptosis-inducing technology to a wider range of cancers.

• VDA-1275

  This is a potent small molecule and new chemical entity in the preclinical stage, developed by Vidac Pharma for the treatment of solid tumors. VDA-1275 represents the company's commitment to expanding its oncology portfolio by exploring more targeted and efficient ways to combat cancer, potentially improving outcomes for patients with solid tumors.